EGFR regulation by microRNA in lung cancer: Correlation with clinical response and survival to gefitinib and EGFR expression in cell lines

Annals of Oncology

Volumn 19, Issue 6, 2008, Pages 1053-1059

  Weiss, G J ^a   Bemis, L T ^b   Nakajima, E ^c   Sugita, M ^d   Birks, D K ^b   Robinson, W A ^b   Varella Garcia, M ^b   Bunn Jr , P A ^b   Haney, J ^d   Helfrich, B A ^b   Kato, H ^c   Hirsch, F R ^b   Franklin, W A ^d  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Epidermal growth factor receptor; Gefitinib; MicroRNA; Non small cell lung cancer

Indexed keywords

BIOLOGICAL MARKER; GEFITINIB; MICRORNA; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER SURVIVAL; CHROMOSOME 3P; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENE LOSS; GENE MUTATION; GENE SEQUENCE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; GENE EXPRESSION; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MICRORNAS; QUINAZOLINES; SURVIVAL ANALYSIS;

EID: 44849091213     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn006     Document Type: Article

References (26)

1. Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539-4544.
2. Weiss GJ. Bunn PA Jr, Camidge DR. From radiotherapy to targeted therapy: 20 years in the management of non-small-cell lung cancer. Oncology (Williston Park) 2006; 20: 1515-1524.
3. Parra HS, Cavina R, Latteri F et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 2004; 91: 208-212.
4. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
5. Dziadziuszko R, Hirsch FR, Varella-Garcia M, Bunn PA Jr. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization - why when, and how? Clin Cancer Res 2006; 12: 4409s-4415s.
6. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5034-5042.
7. Hirsch FR, Varella-Garcia M, Cappuzzo F et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007; 18: 752-760.
8. Yatabe Y, Mitsudomi T. Epidermal growth factor receptor mutations in lung cancers. Pathol Int 2007; 57: 233-244.
9. Dziadziuszko R, Holm B, Skov BG et al. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann Oncol 2007; 18(3): 447-452.
10. Galin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529.
11. Kumar MS, Lu J, Mercer KL et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet 2007; 39: 673-677.
12. Eder M, Scherr M. MicroRNA and lung cancer. N. Engl J Med 2005; 352: 2446-2448.
13. Scott GK, Goga A, Bhaumik D et al. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282: 1479-1486.
14. Wistuba II, Behrens C, Virmani AK et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000; 60: 1949-1960.
15. van Bokhoven A, Gaires A, Maria MD et al. Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines. Prostate 2003; 57: 226-244.
16. Kallioniemi A. Kallioniemi OP, Sudar D et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258: 818-821.
17. Shaffer LG, Tommerup N. ISCN 2005: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger 2005.
18. Helfrich BA, Raben D, Varella-Garcia M et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 2006; 12: 7117-7125.
19. T Method. Methods 2001; 25: 402-408.
20. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-3807.
21. Therasse P, Arbuck SO, Elsenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
22. Fortna A, Kim Y, MacLaren E et al. Lineage-specific gene duplication and loss in human and great ape evolution. PLoS Biol 2004; 2: E207.
23. Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-647.
24. Kaneda H, Tamura K, Kurata T et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 46: 247-254.
25. Miller VA, Kris MO, Sha N et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 1103-1109.
26. van Puijenbroek R, Bosquee L, Meert AP et al. Gefitinib monotherapy in advanced nonsmall cell lung cancer: A large Western community implementation study. Eur Respir J 2007; 29: 128-133.